Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune ...

First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - ...

Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated ...

The call will provide a corporate and financial update and go forward operational plans.

MONTREAL and CHARLOTTE, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ending September 30, 2025, and ...

Third quarter 2025 revenue grew more than tenfold year-over-year and 30% sequentially quarter-over-quarter, demonstrating both the immediate benefits from Firefly’s May 2025 acquisition of Evoke ...

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical ...

"Together, these highlight the fact that oral corticosteroids contribute to burden, even intermittently used," Oppenheimer ...

Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies ...

Conference call will be held today, Tuesday, November 11 at 9:00 am ETCARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today ...

Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates ...